StemCells (STEM) PT Cut to $3 at Maxim Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
UPDATE: StemCells (STEM) Declines After Shares Resume Trading
December 23, 2015 8:10 AM EST(Updated - December 23, 2015 8:16 AM EST)
StemCells (NASDAQ: STEM) Declines After Shares Resume Trading
... MoreStemCells (STEM) to Suspend Phase II Radiant Study in GA-AMD, Cut Workforce by 25%
December 23, 2015 8:07 AM ESTStemCells, Inc. (NASDAQ: STEM) today announced a strategic realignment to fully focus the Companys resources on its proprietary HuCNS-SC® platform technology for the treatment of chronic spinal cord injury (SCI).
Evidence of efficacy from the Companys ongoing clinical trials in chronic SCI offers therapeutic promise to restore lost function previously considered unrecoverable. StemCells recently reported a pattern of improvements in both strength and motor function, six months post-transplant of its proprietary HuCNS-SC cells, in the first cohort of its Phase II Pathway Study in cervical spinal cord injury. These interim... More
StemCells (STEM) Halted, News Pending
December 23, 2015 8:01 AM ESTStemCells (NASDAQ: STEM) Halted, News Pending
... More